<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2018-18-86-91</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-2798</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕВМАТОЛОГИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RHEUMATOLOGY</subject></subj-group></article-categories><title-group><article-title>Значение определения сывороточного прокальцитонина в дифференциальной диагностике инфекций и ревматических заболеваний</article-title><trans-title-group xml:lang="en"><trans-title>Significance of serum procalcitonin for differentiating infections from rheumatic diseases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарасова</surname><given-names>Г. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarasova</surname><given-names>G. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тарасова Галина Михайловна – кандидат медицинских наук, старший научный сотрудник лаборатории изучения роли инфекций при ревматических заболеваниях.</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белов</surname><given-names>Б. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Belov</surname><given-names>B. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белов Борис Сергеевич – доктор медицинских наук, зав. лабораторией изучения роли инфекций при ревматических заболеваниях.</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дилбарян</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Dilbaryan</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дилбарян Ани Георгиевна – врач-терапевт.</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Буханова</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bukhanova</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Буханова Дарья Валерьевна – аспирант лаборатории изучения роли инфекций при ревматических заболеваниях.</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Глухова</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Glukova</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Глухова Светлана Ивановна – кандидат физико-математических наук, старший научный сотрудник учебно-методического отдела.</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Nasonova Research Institute of Reumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>17</day><month>11</month><year>2018</year></pub-date><volume>0</volume><issue>18</issue><fpage>86</fpage><lpage>91</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Тарасова Г.М., Белов Б.С., Дилбарян А.Г., Буханова Д.В., Глухова С.И., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Тарасова Г.М., Белов Б.С., Дилбарян А.Г., Буханова Д.В., Глухова С.И.</copyright-holder><copyright-holder xml:lang="en">Tarasova G.M., Belov B.S., Dilbaryan A.G., Bukhanova D.V., Glukova S.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/2798">https://www.med-sovet.pro/jour/article/view/2798</self-uri><abstract><p>Дифференциальная диагностика между активностью ревматического заболевания (РЗ) и развитием инфекционного процесса нередко крайне сложна из-за сходства клинических и лабораторных проявлений, а также их недостаточной  специфичности.</p><sec><title>Цель исследования</title><p>Цель исследования: оценить значимость прокальцитонинового (ПКТ) теста в качестве специфического маркера генерализованной и локальной инфекции у пациентов с РЗ, а также определить его роль в оценке активности воспалительного процесса при различных РЗ.</p></sec><sec><title>Материал и методы</title><p>Материал и методы: в ходе ретроспективного исследования изучены истории болезни 145 больных (женщины – 101, мужчины – 44, возраст – 3–79 лет), находившихся на стационарном обследовании и лечении в НИИР им. В.А. Насоновой. Концентрацию ПКТ в сыворотке крови определяли количественным электрохемилюминесцентным методом на анализаторе Сobas E 411 (Roshe, Швейцария).</p></sec><sec><title>Результаты</title><p>Результаты: инфекционный процесс диагностирован у 85 человек, генерализованный – у 13, локальный – у 72. Локальные инфекции по своему течению разделены на легкие – 41 и тяжелые – 31. У пациентов с генерализованной инфекцией уровень ПКТ в 77% случаев превышал 2,0 нг/мл, в 46,2% случаев – 10,0 нг/мл. Медиана (Ме) ПКТ в группе с генерализованной инфекцией составила 3,6 [2,26; 10,5]. В случае локальной инфекции тяжелого течения Ме ПКТ превышала пороговые значения и составила 0,49 [0,19; 1,5] нг/мл, при локальной инфекции легкого течения показатели ПКТ достоверно не отличались от показателей группы без инфекции (Ме = 0,13 [0,08; 0,25] и 0,09 [0,06;0,18] нг/мл, р&gt;0,05). Максимальные значения ПКТ в отсутствие инфекции и при высокой активности ревматического процесса выявлены при болезни Стилла взрослых (БСВ) – Ме = 0,26  [0,10; 0,61] нг/мл, умеренное повышение – при ювенильном идиопатическом артрите (ЮИА) с системным началом – Ме = 0,2 [0,14, 0,24] нг/мл, ювенильном ревматоидном артрите (ЮРА) – Ме = 0,2 [0,1; 0,26] нг/мл, системной красной волчанке (СКВ) – Ме = 0,19 [0,11, 0,39] нг/мл.</p></sec><sec><title>Выводы</title><p>Выводы: определение уровня ПКТ, несомненно, способствует диагностике генерализованных инфекций, а также дифференциальной диагностике системных РЗ и инфекционного процесса. Для определения порогового значения ПКТ при различных РЗ необходимы дальнейшие исследования.</p></sec></abstract><trans-abstract xml:lang="en"><p>Differentiation between flare of a rheumatic disease (RD) and the development of infectious process is often extremely difficult due to the similarity of clinical and laboratory manifestations, as well as their lack of specificity.</p><sec><title>Objective of the study</title><p>Objective of the study: to assess the significance of procalcitonin (PCT) test as a specific marker of generalized and local infection in patients with RD, and also to determine its role in assessing the inflammatory process activity in various RDs.</p></sec><sec><title>Material and methods</title><p>Material and methods: The case records of 145 patients (101 women , 44 men,  age of 3–79 years), who were undergoing inpatient examination and treatment at Nasonova Research Institute of Reumatology, were examined during the retrospective study. The serum PCT level was determined by the quantitative electrochemiluminescence method using  the Cobas E 411 analyzer (Roshe, Switzerland).</p></sec><sec><title>Results</title><p>Results: The infectious process was diagnosed in 85 patients, the generalized one in 13 and the local one in 72. Local infections were divided into those with the light course – 41 and with the severe course – 31. In patients with generalized infection, the PCT level exceeded 2.0 ng/ml in 77% of cases and  in 10.0 ng/ml in 46.2% of cases.  Median (Me) PCT was 3.6 [2.26; 10.5] in the group with generalized infection. Me PKT exceeded the threshold values   and amounted to 0.49 [0.19; 1.5] ng/ml in the case of a local infection with the severe course,  PCT indices did not significantly differ from those of the group without infection (Me = 0.13 [0.08; 0.25] and 0.09 [0.06; 0.18 ] ng / ml, p&gt; 0.05).with a local infection of the lungs, The maximum values   of PCT in the absence of infection and with a high activity of the rheumatic process were detected in patients with Adult-onset Still’s Disease (AOSD) – Me = 0.26 [0.10; 0.61] ng/ml, moderate increase was detected in patients with systemic-onset juvenile idiopathic arthritis (JIA)– Me = 0.2 [0.14, 0.24] ng/ml, juvenile rheumatoid arthritis (JRA) – Me = 0.2 [0.1; 0.26] ng/ml, systemic lupus erythematosus (SLE) – Me = 0.19 [0.11, 0.39] ng/ml.</p></sec><sec><title>Conclusions</title><p>Conclusions: Determining PCT level undoubtedly contributes to the diagnosis of generalized infections, and differential diagnosis of systemic RD from the infectious process. Further research is required to determine the PCT threshold value for various RDs.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>прокальцитониновый тест</kwd><kwd>ревматические заболевания</kwd><kwd>генерализованные инфекции</kwd><kwd>локальные инфекции</kwd></kwd-group><kwd-group xml:lang="en"><kwd>procalcitonin test</kwd><kwd>rheumatic diseases</kwd><kwd>generalized infections</kwd><kwd>local infections</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet, 2004, 363(9409): 600- 607.</mixed-citation><mixed-citation xml:lang="en">Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet, 2004, 363(9409): 600- 607.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Becker KL, Nylen ES, White JC et al. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab, 2004, 89(4): 1512-1525.</mixed-citation><mixed-citation xml:lang="en">Becker KL, Nylen ES, White JC et al. Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab, 2004, 89(4): 1512-1525.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Dahaba AA, Metzler H. Procalcitonin’s role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiol, 2009, 75(7-8): 447-452.</mixed-citation><mixed-citation xml:lang="en">Dahaba AA, Metzler H. Procalcitonin’s role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiol, 2009, 75(7-8): 447-452.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tavares E, Minano FJ. Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies. Clin Sci (Lond), 2010, 119(12): 519-534.</mixed-citation><mixed-citation xml:lang="en">Tavares E, Minano FJ. Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies. Clin Sci (Lond), 2010, 119(12): 519-534.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ромашева М.Л., Прошин Д.Г. Диагностика сепсиса у больных в критических состояниях. Общая реаниматология, 2007, 3(4): 34-36.</mixed-citation><mixed-citation xml:lang="en">Romasheva ML, Proshin DG. Diagnosis of sepsis in critically ill patients. Obschay Reanimatologia, 2007, 3 (4): 34-36.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Schuetz P, Chiappa V, Briel M, Greenwald JL Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med, 2011, 171(15): 1322-1331.</mixed-citation><mixed-citation xml:lang="en">Schuetz P, Chiappa V, Briel M, Greenwald JL Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med, 2011, 171(15): 1322-1331.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Uzzan В, Cohen R, Nicolas P et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med, 2006, 34(7): 1996-2003.</mixed-citation><mixed-citation xml:lang="en">Uzzan В, Cohen R, Nicolas P et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med, 2006, 34(7): 1996-2003.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Лобань Н.В., Федотова Н.Ю., Лысенко А.С. Опыт применения количественного теста на прокальцитонин для оценки эффективности антибактериальной терапии у детей первого года жизни. Вопр. диагн. педиат., 2009, 1(1): 37-40.</mixed-citation><mixed-citation xml:lang="en">Loban NV, Fedotova NYu, Lysenko AS. Experience in using a quantitative procalcitonin test to assess the effectiveness of antibiotic therapy in infants. Vopr. Diagn. Pediat, 2009, 1 (1): 37-40.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Muller В, Christ-Crain M, Nylen ES et al. Limits to the use of the procalcitonin level as a diagnostic marker. Clin Infect Dis, 2004, 39(12): 1867-1868.</mixed-citation><mixed-citation xml:lang="en">Muller В, Christ-Crain M, Nylen ES et al. Limits to the use of the procalcitonin level as a diagnostic marker. Clin Infect Dis, 2004, 39(12): 1867-1868.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Meisner M. Procalcitonin (PCT). A new, innovative infection parameter. Biochemical and clinical aspects. Georg Thieme Verlag, Stuttgard – New York. 2000: 162-175.</mixed-citation><mixed-citation xml:lang="en">Meisner M. Procalcitonin (PCT). A new, innovative infection parameter. Biochemical and clinical aspects. Georg Thieme Verlag, Stuttgard – New York. 2000: 162-175.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Meisner M, Schmidt J, Huttner H, Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impared renal function. Intensive Care Med, 2000, 26: 212-216.</mixed-citation><mixed-citation xml:lang="en">Meisner M, Schmidt J, Huttner H, Tschaikowsky K. The natural elimination rate of procalcitonin in patients with normal and impared renal function. Intensive Care Med, 2000, 26: 212-216.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Moosig F, Csernok E, Reinhold-Keller E et al. Elevated procalcitonin levels in active Wegener’s granulomatosis. J Rheumatol, 1998, 25(8): 15311533.</mixed-citation><mixed-citation xml:lang="en">Moosig F, Csernok E, Reinhold-Keller E et al. Elevated procalcitonin levels in active Wegener’s granulomatosis. J Rheumatol, 1998, 25(8): 15311533.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Okada Y, Minakami H, Tomomasa T et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect, 2004, 48(2): 199-205.</mixed-citation><mixed-citation xml:lang="en">Okada Y, Minakami H, Tomomasa T et al. Serum procalcitonin concentration in patients with Kawasaki disease. J Infect, 2004, 48(2): 199-205.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Scire CA, Cavagna L, Perotti C et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol, 2006, 24(2): 123-128.</mixed-citation><mixed-citation xml:lang="en">Scire CA, Cavagna L, Perotti C et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. Clin Exp Rheumatol, 2006, 24(2): 123-128.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Schwenger V, Sis J, Breitbart A, Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection, 1998, 26(5): 274-276.</mixed-citation><mixed-citation xml:lang="en">Schwenger V, Sis J, Breitbart A, Andrassy K. CRP levels in autoimmune disease can be specified by measurement of procalcitonin. Infection, 1998, 26(5): 274-276.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tamaki K, Kogata Y, Sugiyama D et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol, 2008, 35(1): 114-119.</mixed-citation><mixed-citation xml:lang="en">Tamaki K, Kogata Y, Sugiyama D et al. Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol, 2008, 35(1): 114-119.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Лапин С.В., Маслянский А.Л., Лазарева Н.М. и др. Значение количественного определения прокальцитонина для диагностики септических осложнений у больных с аутоиммунными ревматическими заболеваниями. Клиническая лабораторная диагностика, 2013, 1: 28-33.</mixed-citation><mixed-citation xml:lang="en">Lapin SV, Maslyansky AL, Lazareva NM, et al. The significance of quantitative procalcitonin assay for the diagnosis of septic complications in patients with autoimmune rheumatic diseases. Klinicheskaya Laboratornaya Diagnostika, 2013, 1: 28-33.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Wu JY, Lee SH, Shen CJ et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum, 2012 Sep, 64(9): 3034-3042.</mixed-citation><mixed-citation xml:lang="en">Wu JY, Lee SH, Shen CJ et al. Use of serum procalcitonin to detect bacterial infection in patients with autoimmune diseases: a systematic review and meta-analysis. Arthritis Rheum, 2012 Sep, 64(9): 3034-3042.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
